Ethypharm India, subsidiary of leading French Drug Delivery Company Ethypharm SA, has entered into out-licensing and supply contract agreements with Shantha Biotechnics for its Ondansetron Flashtab in India.

The products will be supplied from Ethypharm's manufacturing facility near Mumbai as finished and packaged formulations for which Shantha Biotechnics will handle the marketing and distribution, according to the company announcement.

Ondansetron is indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, certain radiotherapies, and the prevention of postoperative nausea and vomiting. Ondansetron Flashtab is a formulation providing an effective alternative to the conventional Ondansetron tablet, added the company officials.

"As the tablet does not need to be swallowed with water, it is a particularly useful formulation for patients who have difficulty with swallowing or who do not feel able to drink, especially cancer patients," said Ajey Kumar, CEO of Ethypharm India. "Introduction of Ondansetron Flashtab showcases our strength in developing innovative solutions in the fast growing NDDS segment," he added.

Merieux Alliance, the French vaccine major based in Lyon, has recently acquired 60 per cent stake in Shantha Biotechnics, finding its potential to make cutting edge technologies available for the patient community. The company is also exploring more possibilities of partnerships to facilitate innovations in research and development.